First Cancer Biosim Approved in EU

Source: Maeil Business News Korea

Feb 26, 2017

South Korea-based Celltrion Inc. announced that the European Commission has granted marketing authorization to its blood cancer treatment, Truxima, a biosimiliar to Roche’s best-selling cancer drug, Rituxan.

Truxima is the first blood cancer biosimiar approved in Europe. The EC’s approval is effective in 28 European Union members and three European Economic Area countries - Norway, Iceland and Lichtenstein.

It is expected that Truxima will enter the market with a potential 30% reduction on the price of Roche's Rituxan.

Read the Pulse article

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments